Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2006 Dec;47(12):1327-1333. Korean.
    Published online Dec 31, 2006.
    https://doi.org/10.4111/kju.2006.47.12.1327
    Copyright © 2006 The Korean Urological Association
    Original Article

    The Characteristics of Voiding Difficulty in Women and the Effect of Tamsulosin

    Jun Ha Lee, Hyo Sin Kim and Ji Youl Lee
      • Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
    • Corresponding author (Email: uroljy@catholic.ac.kr )
    Received June 09, 2006; Accepted September 08, 2006.

    Abstract

    Purpose

    The aim of this study was to define the characteristics of female voiding difficulty, and evaluate the effects of the alpha-blocker, tamsulosin, on the symptoms in those patients.

    Materials and Methods

    148 patients, who complained of voiding difficulty between March 2002 and September 2004, were retrospectively evaluated. 32 patients with anatomical and neuropathic causes were excluded, with the remaining 116 assigned to 4 groups from their urodynamic evaluations: group I, bladder outlet obstruction (BOO) only; group II, BOO plus an overactive bladder (OAB); group III, detrusor underactivity (DU) only; and group IV, DU plus an OAB. After 2 weeks of observation, tamsulosin, 0.2mg/d, was prescribed in all groups, with the patients re-evaluated after 3 months.

    Results

    58 (50%), 23 (19.8%), 20 (17.3%) and 15 (12.9%) of the 116 study subjects were placed into groups I, II, III and IV, respectively. In group I, 45 (77.5%) had symptomatic improvement after taking tamsulosin for 3 months, and in group II improvement was observed in 73.9% (17/23) of patients. In groups III and IV; however, improvements were seen in only 25 (5/20) and 13.3% (2/15) of cases, respectively. Dizziness, postural hypotension and urinary incontinence occurred in some patients, but these disappeared after the medication was discontinued.

    Conclusions

    81 patients (69.8%) had a bladder outlet obstruction, without detrusor underactivity, and 62 (76.5%) of these exhibited a voiding improvement after taking tamsulosin for three months. However, in patients with detrusor underactivity, the response rate was very low (20%).

    Keywords
    Urination disorders; Adrenergic alpha-blockers; Female

    Tables

    Table 1
    The characteristics of the patients before treatment (means±SE)

    Table 2
    Comparison of the clinical parameters pre- and post-treatment in groups I and II (means±SE)

    Table 3
    Comparison of the clinical parameters pre- and post-treatment in groups III and IV (means±SE)

    Table 4
    Effect of tamsulosin in each group

    References

      1. Chassagne S, Bernier PA, Haab F, Roehrborn CG, Reisch JS, Zimmern PE. Proposed cutoff values to define bladder outlet obstruction in women. Urology 1998;51:408–411.
      1. Groutz A, Blaivas JG, Chaikin DC. Bladder outlet obstruction in women: definition and characteristics. Neurourol Urodyn 2000;19:213–220.
      1. Yamanishi T, Yasuda K, Kamai T, Tsujii T, Sakakibara R, Uchiyama T, et al. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol 2004;11:88–96.
      1. Abrams P, Blaivas JG, Stanton SL, Anderson JT. The standardization of terminology of lower urinary tract function recommended by The International Continence Society. Int Urogynecol Pelvic Floor Dysfunct 1990;1:45–46.
      1. Quesada EM, Scott FB, Cardus D. Functional classification of neurogenic bladder dysfunction. Arch Phys Med Rehabil 1968;49:692–697.
      1. Wein AJ. Classification of neurogenic voiding dysfunction. J Urol 1981;125:605–609.
      1. Groutz A, Blaivas JG. Non-neurogenic female voiding dysfunction. Curr Opin Urol 2002;12:311–316.
      1. Mayo ME, Lloyd-Davies RW, Shuttleworth KE, Tighe JR. The damaged human detrusor: functional and electron microscopic changes in disease. Br J Urol 1973;45:116–125.
      1. Groutz A, Gordon D, Wolman I, Jaffa A, Kupferminc MJ, Lessing JB. Persistent postpartum urinary retention in contemporary obstetric practice. Definition, prevalence and clinical implications. J Reprod Med 2001;46:44–48.
      1. Stanton SL, Ozsoy C, Hilton P. Voiding difficulties in the female: prevalence, clinical and urodynamic review. Obstet Gynecol 1983;61:144–147.
      1. Dwyer PL, Desmedt E. Impaired bladder emptying in women. Aust N Z J Obstet Gynaecol 1994;34:73–78.
      1. Clarke B. The role of urodynamic assessment in the diagnosis of lower urinary tract disorders. Int Urogynecol J Pelvic Floor Dysfunct 1997;8:196–199.
      1. Groutz A, Gordon D, Lessing JB, Wolman I, Jaffa A, David MP. Prevalence and characteristics of voiding difficulties in women: are subjective symptoms substantiated by objective urodynamic data? Urology 1999;54:268–272.
      1. Haylen BT. Voiding difficulty in women. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:1–3.
      1. Haylen BT, Law MG, Frazer MI, Sculz S. Urine flow rates and residual urine volumes in urogynecology patients. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:378–383.
      1. Costantini E, Mearini E, Pajoncini C, Biscotto S, Bini V, Porena M. Uroflowmetry in female voiding disturbances. Neurourol Urodyn 2003;22:569–573.
      1. Axelrod SL, Blaivas JG. Bladder neck obstruction in women. J Urol 1987;137:497–499.
      1. Massey JA, Abrams PH. Obstructed voiding in the female. Br J Urol 1988;61:36–39.
      1. Kim HS, Lee U, Lee MH, Choo MS. Cut-off value for bladder outlet obstruction in pressure-flow study in female: a prospective study. Korean J Urol 2001;42:1146–1151.
      1. O'Riordan JI, Doherty C, Javed M, Brophy D, Hutchinson M, Quinlan D. Do α-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol 1995;153:1114–1116.
      1. Chess-Williams R. The use of alpha-adrenoceptor antagonists in lower urinary tract disease. Expert Opin Pharmacother 2002;3:167–172.
      1. Mobley DF. Phenoxybenzamine in the management of neurogenic vesical dysfunction. J Urol 1976;116:737–738.
      1. Sakakibara R, Hattori T, Uchiyama T, Suenaga T, Takahashi H, Yamanishi T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 2000;79:191–195.
      1. Schulte-Baukloh H, Michael T, Miller K, Knispel HH. Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. BJU Int 2002;90:716–720.
      1. Ek A, Alm P, Andersson KE, Persson CG. Adrenergic and cholinergic nerves of the human urethra and urinary bladder: a histochemical study. Acta Physiol Scand 1977;99:345–352.
      1. Kawabe K, Niijima T. Use of an alpha 1-blocker, YM-12617, in micturition difficulty. Urol Int 1987;42:280–284.
      1. Kumar A, Mandhani A, Gogoi S, Srivastava A. Management of functional bladder neck obstruction in women: use of alpha-blockers and pediatric resectoscope for bladder neck incision. J Urol 1999;162:2061–2065.
      1. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, et al. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 1995;47:267–270.
      1. Schwin DA. The role of α1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001;88 Suppl 2:27–34.
      1. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002;62:135–167.
    Cited by
    Crossref 2
    Google Scholar 
    Scopus 2
    MeSH Terms
    Adrenergic alpha-Antagonists
    Dizziness
    Female
    Humans
    Hypotension, Orthostatic
    Retrospective Studies
    Urinary Bladder Neck Obstruction
    Urinary Bladder, Overactive
    Urinary Incontinence
    Urination Disorders
    Urodynamics
    Metrics
    Share
    Tables
    slide
    slide
    slide
    slide

    1 / 4

    PERMALINK